All In Biotech

NDA 008372 · Mallinckrodt Ireland

Acthar Gel

Corticotropin · Injection · Adrenocorticotropic Hormone

Orphan

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1952

Apr 29, 1952

Approved uses

1

Original approval plus efficacy supplements

Registered trials

176

26 Phase 3, 13 recruiting

FAERS reports

4,450

1,711 serious, 61 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 13, 2026.

Acthar Gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. ( 1.1 ) Acthar Gel is indicated for the treatment of exacerbations of multiple sclerosis in adults. ( 1.2 ) Acthar Gel may be used for the following disorders and diseases: rheumatic ( 1.3 ); collagen ( 1.4 ); dermatologic ( 1.5 ); allergic states ( 1.6 ); ophthalmic ( 1.7 ); respiratory ( 1.8 ); and edematous state. ( 1.9 ) 1.1 Infantile Spasms Acthar Gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. 1.2 Multiple Sclerosis Acthar Gel is indicated for the treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown Acthar Gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease. 1.3 Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis; Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); Ankylosing spondylitis. 1.4 Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis). 1.5 Dermatologic Diseases Severe erythema multiforme, Stevens-Johnson syndrome. 1.6 Allergic States Serum sickness. 1.7 Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis; iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis; anterior segment...

Mechanism: The mechanism of action of Acthar Gel in the treatment of infantile spasms is unknown. Acthar Gel and endogenous ACTH stimulate the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances. Prolonged administration of large doses of Acthar Gel induces hyperplasia and hypertrophy of the adrenal cortex and continuous high output of cortisol, corticosterone and weak androgens. The release of endogenous ACTH is under the influence of the nervous system via the regulatory hormone released from the hypothalamus and by a negative corticosteroid...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 29, 1952 Original approval · Type 5 - New Formulation or New Manufacturer
4 products under this application
  • ACTHAR GEL · CORTICOTROPIN 40 UNITS/ML · INJECTABLE, INJECTION · Discontinued
  • ACTHAR GEL (AUTOINJECTOR) · CORTICOTROPIN 80 UNITS/ML · INJECTABLE, INJECTION · Prescription
  • ACTHAR GEL (AUTOINJECTOR) · CORTICOTROPIN 40 UNITS/0.5ML · INJECTABLE, INJECTION · Prescription
  • ACTHAR GEL · CORTICOTROPIN 80 UNITS/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Corticotropin" as an intervention, any sponsor and status, largest first.

All 176 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • injection site bruising385
  • fatigue381
  • product dose omission issue317
  • injection site pain301
  • headache268
  • insomnia255
  • condition aggravated198
  • weight increased198
  • pain191
  • drug ineffective180
  • blood glucose increased172
  • asthenia161

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20091
20101
20117
201224
201346
201473
201565
201664
201777
2018104
201985
202041
202143
202247
202359
202463
202583
20263,566

Recalls

2 FDA enforcement reports for this application.

  • Aug 6, 2026 · Class II · Ongoing

    Presence of particulate matter: glass and stopper piece

  • Feb 6, 2024 · Class II · Ongoing

    cGMP deviations: Temperature excursion due to shipping delay from manufacturer to distributor. Affected distributor has been notified.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 595 on PubMed

Sponsor: Mallinckrodt Ireland · Also marketed as Acthar Gel (Autoinjector)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.